Category - Developments

Developments

MolDX issues Bionano proposed LCD

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics (NASDAQ: BNGO) has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors...

September 10, 2026

Developments

Ocumetics initiates patient recruitment for next-gen lens study

Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical...

September 8, 2026

Developments

eXoZymes selects Curia as CDMO for NCT

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N...

September 8, 2026

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Developments

cbdMD to acquire Twinlab brands

cbdMD (NYSE American: YCBD) has announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea...

September 2, 2026

Developments

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Purple Biotech (NASDAQ/TASE: PPBT) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering tri-specific antibody constructs and methods of use...

September 2, 2026

Developments

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Developments

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer. Mr...

September 1, 2026

Developments

Karyopharm submits sNDA for XPOVIO + ruxolitinib in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for...

August 31, 2026

Developments

TELA announces COO/CFO transition and cost reduction

TELA Bio (NASDAQ: TELA) has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. In a statement, Heather Getz, CEO of TELA, commented...

August 31, 2026

Category - Developments

Subscribe